Our State-of-the-Art
Chemistries Drive Innovation.
At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed.
Featured News
Flamingo Therapeutics Announces Poster Presentation on the Immune-Modulatory Effects of Danvatirsen at the American Association for Cancer Research (AACR) Annual Meeting
Flamingo Therapeutics (“Flamingo”) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting being held in Chicago, IL from April 25-30, 2025.